Introduction: It is known that warfarin treatment is problematic, due to its narrow therapeutic range and to the great interindividual variability. Numerous papers have shown the important contribution of CYP2C9 and VKORC1 genetic variants to this variability. Recently, a new SNP within the CYP4F2 gene was found associated with warfarin dose in the USA.
Borgiani, P., Ciccacci, C., Forte, V., Sirianni, E., Novelli, L., Bramanti, P., et al. (2009). CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. PHARMACOGENOMICS, 10(2), 261-266 [10.2217/14622416.10.2.261].
CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population
BORGIANI, PAOLA;CICCACCI, CINZIA;NOVELLI, GIUSEPPE
2009-02-01
Abstract
Introduction: It is known that warfarin treatment is problematic, due to its narrow therapeutic range and to the great interindividual variability. Numerous papers have shown the important contribution of CYP2C9 and VKORC1 genetic variants to this variability. Recently, a new SNP within the CYP4F2 gene was found associated with warfarin dose in the USA.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
